Health
FDA Approves Nelkarmi for Previously Treated ALK-Positive Lung Cancer, Based on a 49 Percent Response Rate
Neladalkib is cleared for patients who have already tried alectinib or other ALK pills. Response and durability come from a single-arm trial, and the approval is conditional on further data.
Nov 19, 2026

